Show simple item record

dc.contributor.authorBodei, L
dc.contributor.authorSrirajaskanthan, R
dc.contributor.authorGrana, CM
dc.contributor.authorBaldari, S
dc.contributor.authorShah, T
dc.contributor.authorLamarca, Angela
dc.contributor.authorCourbon, F
dc.contributor.authorScheidhauer, K
dc.contributor.authorBaudin, E
dc.contributor.authorRoussy, G
dc.contributor.authorThanh, XMT
dc.contributor.authorHouchard, A
dc.contributor.authorPrasad, V
dc.date.accessioned2020-06-15T12:57:35Z
dc.date.available2020-06-15T12:57:35Z
dc.date.issued2020en
dc.identifier.citationBodei L, Srirajaskanthan R, Grana C, Baldari S, Shah T, Lamarca A, et al. Tumor growth rate (TGR) to monitor growth/predict response to lanreotide autogel use before, during and after PRRT in advanced GEP-NETS: data from the PRELUDE study. Pancreas. 2020;49(3):464-en
dc.identifier.urihttp://hdl.handle.net/10541/622949
dc.language.isoenen
dc.titleTumor growth rate (TGR) to monitor growth/predict response to lanreotide autogel use before, during and after PRRT in advanced GEP-NETS: data from the PRELUDE studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMemorial Sloan Kettering Cancer Center, New Yorken
dc.identifier.journalPancreasen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record